Tenon Medical, Inc.
For the period ended Aug 13, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 13, 2026 · Filed Aug 13, 2026
Use the contents to explore the available documents and sections.
TNON$1.640.0%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · (In thousands, except share data)
(In thousands, except share data)
| June 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $1,677 | $3,756 |
| Accounts receivable, net | 1,947 | 1,698 |
| Inventory | 783 | 1,054 |
| Prepaid expenses and other current assets | 400 | 260 |
| Total current assets | 4,807 | 6,768 |
| Property and equipment, net | 771 | 918 |
| Deposits | 51 | 51 |
| Operating lease right-of-use asset | 1,431 | 131 |
| Intangible assets, net | 455 | 485 |
| Goodwill | 2,407 | 2,407 |
| TOTAL ASSETS | $9,922 | $10,760 |
| Liabilities and Stockholders’ (DEFICIT) EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $628 | $845 |
| Accrued expenses | 1,952 | 1,637 |
| Current portion of accrued commissions | 674 | 590 |
| Current portion of operating lease liability | 215 | 141 |
| Current portion of contingent consideration | 29 | — |
| Convertible notes | 4,332 | — |
| Derivative liability | 475 | — |
| Total current liabilities | 8,305 | 3,213 |
| Accrued commissions, net of current portion | 1,250 | 1,514 |
| Operating lease liability, net of current portion | 1,131 | — |
| Contingent consideration, net of current portion | 979 | 993 |
| Total liabilities | 11,665 | 5,720 |
| Stockholders’ (deficit) equity: | ||
| Series A convertible preferred stock, $0.001 par value; 4,500,000 shares authorized at June 30, 2026 and December 31, 2025; 204,159 shares issued and outstanding at June 30, 2026 and December 31, 2025 | 2,622 | 2,622 |
| Series B convertible preferred stock, $0.001 par value; 491,222 shares authorized at June 30, 2026 and December 31, 2025; 86,454 shares issued and outstanding at June 30, 2026 and December 31, 2025 | 452 | 452 |
| Common stock, $0.001 par value; 130,000,000 shares authorized at June 30, 2026 and December 31, 2025; 330,670 and 310,036 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | — | — |
| Additional paid-in capital | 84,011 | 83,268 |
| Accumulated deficit | (88,828) | (81,302) |
| Total stockholders’ (deficit) equity | (1,743) | 5,040 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY | $9,922 | $10,760 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.